Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.67 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20262093 | 0.85 | PTGS1 (0.62) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8792437 | 0.85 | ALDH1A1 (0.57) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27691396 | 0.83 | GABRA1 (0.60) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL28208998 | 0.83 | HSD17B10 (0.61) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3256879 | 0.82 | BCAT2 (0.57) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4854785 | 0.81 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL23969685 | 0.81 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2980845 | 0.80 | BCAT2 (0.68) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27592427 | 0.80 | SMN1; SMN2 (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL24611525 | 0.80 | KDM4E (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| CN-107849035-B | Phenyl heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113286784-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| CN-107849035-A | Phenyl heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2017114377-A1 | BENZYL HETEROCYCLIC COMPOUND DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| CN-101098852-A | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | SMITHKLINE BEECHAM CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| EP-1569929-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS | Virochem Pharma Inc. (CA) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052885-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
| US-4242518-A | Thiophene compounds and their manufacture | BASF AKTIENGESELLSCHAFT (DE) | 1980-12-30 | — | — | US | disclosed |
| US-4239897-A | Thiophene compounds and their manufacture | BASF AKTIENGESELLSCHAFT (DE) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | GABRA1 4093/4885GABRG2 4189/4885GABRB3 4045/4885 |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | DDT, TYR, DDC | GABRA1 659/4885GABRG2 539/4885GABRB3 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.